There is a general consensus in the literature that AD patients with the APOE4 isoform have accelerated onset of dementia, worse memory performance and higher Aβ burden than APOE4 non-carriers [10], though the isoform-dependent effects on tauopathy remain unclear [11, 12]. Here, APOE is linked to Alzheimer disease.